Regulatory perspective of cancer drug development: An overview

Despite the fact postulated that better technology and scientific knowledge will lead to better medical services, the truth is very distinctive. Despite having the most cutting-edge scientific knowledge, America and the majority of Europe ironically have the maximum cancer rates. It shows that using technology and science alone to treat cancer and other diseases is inadequate. Additionally, it is now widely acknowledged that majority of pre-clinical tumour models are insufficient, because more than 95% of substances and molecules that kill cancerous cells in culture or reduce tumours in animals may fail in clinical studies in people. Additionally, the majority of anti-cancer medications which are authorised by regulatory bodies like the FDA have either no impact on survival of cancer patients or may raise by a few months. This is amidst the fact that majority of presently offered chemotherapeutic drugs are very expensive, leading to a lack of affordability.